Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Go Market Go! who wrote (173)	8/8/2006 6:21:03 PM
From: rkrw	Respond to of 3027

Thanks Alfie. Drop not justified on this news since the patent is already being disputed by others. I expect mnta to do a deal with the first filers to get access to the 180 days... <<However, the Hatch-Waxman Act provides that any subsequent ANDA applications will not be approved until 180 days after the earlier of: (1) the date of the first commercial marketing of the first-filed ANDA applicant’s generic drug; or (2) the date of a decision of a court in an action holding the relevant patent invalid, unenforceable or not infringed. The Hatch-Waxman Act therefore effectively grants the first ANDA holder to have its ANDA accepted for review by the FDA with 180 days of marketing exclusivity for the generic product.>>

To: Go Market Go! who wrote (173)	8/8/2006 6:21:51 PM
From: rkrw	Respond to of 3027

Thanks Alfie. Drop not justified on this news since the patent is already being disputed by others. I expect mnta to do a deal with the first filers to get access to the 180 days... <<However, the Hatch-Waxman Act provides that any subsequent ANDA applications will not be approved until 180 days after the earlier of: (1) the date of the first commercial marketing of the first-filed ANDA applicant’s generic drug; or (2) the date of a decision of a court in an action holding the relevant patent invalid, unenforceable or not infringed. The Hatch-Waxman Act therefore effectively grants the first ANDA holder to have its ANDA accepted for review by the FDA with 180 days of marketing exclusivity for the generic product.>>